

Table SI. Demographics of the study population and biological samples in GSE20257 (17).

Parameter	Healthy non-smokers	Healthy smokers	Smokers with COPD ^a
Total patients, n	53	59	23
Sex, n			
Male	38	39	18
Female	15	20	5
Age, years	41.0±11.3	42.9±7.2	51.7±8.4
Ethnicity, n			
Black	24	35	38
White	20	14	57
Other	9	10	3
Smoking history, pack-year	-	27.6±16.9	40.8±27.6
Urine nicotine, ng/ml	-	1216±1604	1069±1126
Urine cotinine, ng/ml	-	1273±1022	1337±592
Blood carboxyhemoglobin, %	0.4±0.7	1.8±1.8	2.9±1.9
Pulmonary function parameters ^b			
FVC	107±13	109±13	97±20
FEV1	105±14	107±14	74±20
FEV1/FVC	81±6	80±5	61±8
TLC	101±13	101±12	103±21
DLCO	99±15	94±11	75±18
GOLD stage (I/II/III) ^a	-	-	9/12/2
Medication use, n			
β-agonist	-	-	7
Anticholinergic	-	-	2
Inhaled corticosteroid	-	-	3
Epithelial cells ^c			

Number recovered, x10 ⁶	6.6±2.9	7.2±3.0	6.7±3.1
Epithelial cells ^d , %	99.1±1.4	99.0±1.5	98.7±1.6
Inflammatory cells, %	0.9±1.4	0.9±1.5	1.3±1.6
Differential cell count			
Ciliated, %	73.0±8.3	65.8±12.4	62.9±10.9
Secretory, %	6.7±3.5	9.0±4.5	12.1±5.6
Basal, %	12.0±5.9	12.6±6.6	12.1±6.2
Undifferentiated, %	7.3±3.2	11.9±6.6	11.5±3.6

^aSmokers with established COPD as defined by the GOLD criteria (39). The COPD smoker group included: GOLD I (n=9), GOLD II (n=12) and GOLD III (n=2). ^bThe pulmonary function testing parameters are given as the % of predicted value with the exception of FEV1/FVC, which is reported as the % observed. The COPD, FVC, FEV1 and FEV1/FVC are post-bronchodilator values. ^cSmall airway epithelium. ^dAs a % of small airway epithelium recovered. Data are presented as mean ± SD unless stated otherwise. COPD, chronic obstructive pulmonary disease; GOLD, The Global Initiative for Chronic Obstructive Lung Disease; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 sec; TLC, total lung capacity; DLCO, diffusing capacity.